Compare Grab Holdings Ltd. (GRAB) vs Mesoblast Limited (MESO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Grab Holdings Ltd. vs Mesoblast Limited — how do they compare? Grab Holdings Ltd. trades at $3.71 (market cap $15.62B), while Mesoblast Limited trades at $19.02 (market cap $2.31B). The key difference: Grab Holdings Ltd. is far larger — about 6.8× Mesoblast Limited's market cap, and Mesoblast Limited is trading nearer its 52-week high, Grab Holdings Ltd. nearer its low. Which is the better fit depends on your goals.
| GRAB | MESO | |
|---|---|---|
Market Cap | $15.62B | $2.31B |
Sector | Technology | Technology |
52-Week High | $6.45 | $20.96 |
52-Week Low | $3.27 | $11.35 |
Enterprise Value | $11.32B | $2.32B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GRAB trades at $3.80, down 3.55% today but showing strong fundamental improvement with revenue growth from $2.8B in 2024 to $3.37B in 2025 and achieving profitability with $268M net income. Technical indicators show a bullish overall signal with neutral oscillators. Recent news highlights CEO share sales and Uber CEO's board departure, creating mixed sentiment despite analyst optimism.
The outlook remains positive with 91.67% analyst buy ratings and a $5.45 consensus target offering 43% upside. Key risks include competitive pressures in Southeast Asia's ride-hailing market and volatile cash flow patterns, but sustained revenue growth and margin expansion support long-term potential.
Mesoblast (MESO) trades at $19.12, up 14.22% with strong bullish technical signals from moving averages. The biotech company shows promising commercial progress with FDA-approved Ryoncil generating $115M annual revenue, though fundamentals reveal significant losses with a -144.33% net income margin and negative EBITDA of -$80.06M. Recent milestones include achieving Phase 3 trial targets for chronic low back pain and receiving a BLA filing number for heart failure treatment.
Investment outlook balances high growth potential from Mesoblast's cellular medicine platform against substantial financial losses and valuation concerns. The company's transition to commercial operations and pipeline advancements present opportunities, while persistent cash burn and negative profitability represent key risks requiring careful monitoring of upcoming clinical and regulatory catalysts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Grab Holdings Ltd.
Grab Holdings Limited operates as a holding company. The Company, through its subsidiaries, develops delivery management, mobility, financial services, and enterprise software solutions. Grab Holdings serves customers worldwide.
Read more on GRAB →About Mesoblast Limited
Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.
Read more on MESO →
